Citeline Podcasts

In this month: Marion Webb highlights Oura’s IPO, new partnerships, and a class-action lawsuit. George Underwood discusses digital tools for early Alzheimer’s detection and Brian Bossetta FDA’s READI-Home Innovation Challenge. Shubham Singh interviews AI longevity firm BAiO.

"Personalized and off‑the‑shelf cancer vaccines are moving from concept to clinic, raising new questions about differentiation, manufacturability, and commercial value. In this episode of Strategic Intent, In Vivo’s David Wild speaks with Marina Udier, CEO of Nouscom, about how the Basel‑based biotech is positioning its viral vector platform in this evolving landscape. They discuss NOUS‑209, an off‑the‑shelf neoantigen vaccine for MSI‑H/dMMR tumors and cancer interception in Lynch syndrome, the company’s personalized program NOUS‑PEV, and what it will take—scientifically, operationally, and commercially—for next‑generation cancer vaccines to succeed."

In this episode of Over the Counter, now also in video, HBW Insight talks to Rachmadi Joesoef, APSMI chair and CEO of Indonesian manufacturer PT Konimex, and Anama O'Reilly, who co-leads APSMI's public affairs and communications committee and heads public affairs for the ASEA zone at Opella, ahead of the association's joint congress with Self-CARER and GP Farmasi Indonesia in Bali. We cover why Indonesia is hosting, what Self-CARER has actually delivered on regulatory streamlining and digital health, why e-labelling deserves more attention than it gets, and the 5am fun run closing the summit. The congress runs 29 October to 1 November at the Paradisus by Meliá, Bali. The open conference covers the afternoon of 30 October and all day 31 October. Register at apsmibalimeeting2026.com, with standard pricing until 20 October. The 5K run on 1 November is a separate sign-up at selfcareamrunbali2026.com.

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Editor-in-Chief Nielsen Hobbs and Prevision Policy Founding Member Mike McCaughan consider the impact of Michael Davis and Karim Mikhail’s promotions to permanent directors of the US Food and Drug Administration’s Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, respectively (1:05), as well as the impact a new commissioner could have on the positions (3:20). They also discuss the FDA’s limited advisory committee schedule and the potential reasons recent senior leadership changes have not spurred more meetings (18:22). More On These Topics From The Pink Sheet US FDA Names Permanent CDER, CBER Directors, Creates AI Deputy Commissioner Post: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-davis-mikhail-gain-permanent-cder-cber-director-positions-47N2SXKPHRB6BCBFLJGUF3Y2NA/ US FDA Advisory Committee Meetings Remain Rare Despite Leadership Changes: https://insights.citeline.com/pink-sheet/product-reviews/us-advisory-committees/us-fda-advisory-committee-meetings-remain-rare-despite-leadership-changes-LD3DFLJYQFDVFCERZXRBVECY3M/

In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.